StreetAlpha.app
Home › Stocks › IMMX

Immix Biopharma, Inc. (IMMX)

Healthcare
$6.96
▼ −1.14%
LAST CLOSE · NOV 20

Immix Biopharma develops CAR T cell therapies, led by NXC-201, for AL amyloidosis and other serious diseases. It last closed at $6.96 on Nov 20, down 1.14% on the day. The next earnings report for IMMX is expected around Thu, Feb 11, 2027, after the close. For the quarter ended Sep 2026, IMMX reported EPS of -$0.19. Over the last 12 months IMMX insiders bought $30K of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is IMMX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold IMMX.

Key Stats

Last 12 months
Results
Net income
−$46.2M
EPS (diluted)
−$0.83
Free cash flow
−$45.2M
Valuation
Market cap
$583.3M
83.8M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$320.3M
At Sep 30
Shareholder equity
$335.1M
Shares outstanding
83.8M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$24.4M−$24.4MFY2021FY2022: −$8.2M−$8.2MFY2022FY2023: −$15.4M−$15.4MFY2023FY2024: −$21.6M−$21.6MFY2024FY2025: −$29.4M−$29.4MFY2025

From IMMX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
Feb 11
Estimated date · After the close
Reported EPS
-$0.19
Quarter ended Sep 2026
Year ago EPS
-$0.24
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.16Dec '24Mar 2025: -$0.15Mar '25Jun 2025: -$0.22Jun '25Sep 2025: -$0.24Sep '25Dec 2025: -$0.28Dec '25Mar 2026: -$0.18Mar '26Jun 2026: -$0.18Jun '26Sep 2026: -$0.19Sep '26Latest -$0.19
Revenue by quarter
Not enough quarters on file yet.
How IMMX moved after its last 1 report
Average move the session after a report ±2.9%
Nov 12, 2026After the close−2.9%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on IMMXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on IMMX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on IMMX

Technical Analysis

IMMX · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 12% below its 20 day and 33% below its 50 day average. It is 39% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 36), near oversold. The nearest support is the Pivot S1 at $6.74, and the nearest resistance the Pivot at $7.12.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 8.7%/day
Key levels
$15.1052 week high+117.0%
$10.23100 day average+47.0%
$9.64200 day average+38.5%
$9.2550 day average+32.9%
$8.36Swing high (Oct 29)+20.1%
$7.7720 day average+11.6%
$7.34Pivot R1+5.5%
$7.12Pivot+2.3%
$6.96Last close
$6.74Pivot S1−3.2%
$3.7852 week low−45.7%
Indicators
RSI (14)35.51Weak, oversold below 30Neutral
MACD-0.53Below its signal lineBearish
Stochastic3.6Near the bottom of its rangeOversold
ADX (14)32.6Trending down
Williams %R-97.0Oversold below −80, overbought above −20Oversold
CCI (20)-123.9Oversold below −100, overbought above 100Oversold
Rate of change−13.7%Change over 10 sessionsBearish
ATR (14)$0.60Typical daily range, 8.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for IMMX

What happened before

See how IMMX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow IMMX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How IMMX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for IMMXHow many large options trades hit IMMX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

IMMX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲103 buying vs 32 selling
  • ▲Held by funds +11.6 pts
  • ▲Funds holding +28
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding137109+25.7%
In funds' top 1043+33.3%
Held by funds78.6%67.1%+11.6 pts
New / increased41 / 6243 / 34+33.8%
Reduced / sold out19 / 1313 / 11+33.3%
Put/call ratio0.00––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See IMMX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

IMMX Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$30K4 buys · 2 insiders
Sold$00 sales · 0 insiders
2025-12 bought $10K2026-11 bought $20KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 18Gabriel S MorrisCFO, PresidentBuy1,418$7.06$10K
Nov 18Ilya M RachmanCEO, ChairmanBuy1,408$7.10$10K
Dec 10, 2025Gabriel S MorrisCFOBuy770$6.58$5K
Dec 10, 2025Ilya M RachmanCEO and ChairmanBuy746$6.67$5K
Sep 17, 2025Ilya M RachmanCEO and ChairmanBuy2,500$2.02$5K
Sep 16, 2025Gabriel S MorrisCFOBuy2,600$1.97$5K
Every insider buy and sale for IMMX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See IMMX insider trades →

From SEC Form 4 filings by IMMX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IMMX is in one of them and how their past IMMX trades turned out.

IMMX in the AI portfolios
Loading…

IMMX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered IMMX in an article yet. Here's the latest on the wider market.

IMMX in the news

About Immix Biopharma

Immix Biopharma is a biopharmaceutical company based in Los Angeles, California. It develops chimeric antigen receptor (CAR) T cell therapies, led by its candidate NXC-201, for AL amyloidosis, a serious disease in which an abnormal protein builds up in organs such as the heart and kidneys. The lead candidate is in clinical trials and is not yet approved for sale. The company's target patients have this disease or other serious conditions where CAR T therapy is not yet an approved treatment.

Headquarters
Los Angeles, CA